A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Twenty-five percent inhaled nitrous oxide improves symptoms of treatment-resistant major depression with fewer adverse effects than the 50% concentration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a Phase 2 trial of 25 and 50% inhaled nitrous oxide for TRD (n = 24) found significant improvement in depressive symptoms in both nitrous oxide groups”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [180]
In the citing paper
“with a significantly lower rate of adverse events in the 25% nitrous oxide group [180]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [180]
In the citing paper
“The antidepressant effects of N2O are mediated through antagonism of the metabotropic glutamatergic NMDA receptors (121).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [121]
In the citing paper
“Nagele and colleagues found that inhaled N2O at a concentration of either 25% or 50% significantly reduced scores on the Hamilton Depression Rating Scale (HDRS) at week 2 in patients with treatment resistant depression.”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [121]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
(2018) · The SAGE Encyclopedia of Educational Research, Measurement, and Evaluation · doi:10.4135/9781506326139.n404 · Cited by 1,528
Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
Jevtović-Todorović, V., Todorovć, S. M., Mennerick, S., Powell, S., Dikranian, K., Benshoff, N., Zorumski, C. F., & Olney, J. W. (1998) · Nature Medicine · doi:10.1038/nm0498-460 · Cited by 676
Self-citationA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482 · cited 1×
“INTRODUCTION Treatment-resistant major depression (TRMD) is a severe form of major depressive disorder (MDD) in which patients fail to respond to multiple standard antidepressant treatments (1, 2).”
BackgroundAbdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Gibbons, R. D., Brown, C. H., Hur, K., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2048 · Cited by 291 · cited 2×
“We note, however, that for the entire 3-month treatment regimen, which involved two treatments with nitrous oxide, a median reduction of 11 HDRS-21 points was observed, which is much larger than that typically seen for traditional antidepressant trials (15, 16).”
BackgroundMethodSelf-citation
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“The antidepressant effects of N2O are mediated through antagonism of the metabotropic glutamatergic NMDA receptors (121).”
BackgroundNew and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Correll, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., Kraemer, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 109
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“In addition, a Phase 2 trial of 25 and 50% inhaled nitrous oxide for TRD ( n = 24) found signi fi cant improvement in depressive symptoms in both nitrous oxide groups, with a signi fi cantly lower rate of adverse events in the 25% nitrous oxide group [180].”
BackgroundRandomized trial of ketamine masked by surgical anesthesia in patients with depression
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00140-x · Cited by 139
“N 2 O has been shown to improve depression symptoms in patients with TRD 14,22 .”
BackgroundInfluentialPulmonary inhalation for disease treatment: Basic research and clinical translations
Wang, B., Wang, L., Yang, Q., Zhang, Y., Qinglai, T., Yang, X., Xiao, Z., Lei, L., & Li, S. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.100966 · Cited by 135
“Inhaled nitrous oxide has a rapid antidepressant effect in patients with refractory depression [351,352].”
BackgroundTreatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P. J., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Van Ameringen, M., & Rodríguez, C. I. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 86
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Classical and non-classical psychedelic drugs induce common network changes in human cortex
Dai, R., Larkin, T. E., Huang, Z., Tarnal, V., Picton, P., Vlisides, P. E., Janke, E., McKinney, A., Hudetz, A. G., Harris, R. E., et al. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120097 · Cited by 61
“More recently, it has been shown that a 25% concentration of nitrous oxide is as effective as a 50% concentration for treatment-resistant major depression (Nagele et al., 2021).”
BackgroundThe role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
“This dose produced signi fi cantly less side effects with retained antidepressant effects up to 2 weeks after the single dose in patients with treatment-resistant depression [166].”
BackgroundRübsam, M.-L., Kruse, P., Dietzler, Y., Kropf, M., Bette, B., Zarbock, A., Kim, S.-C., & Hönemann, C. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-022-02393-z · Cited by 39
“, in children) or during labor, to address treatment-resistant depression, and as a strategy for preventing chronic postsurgical pain in particular populations.(39,56,57) Nevertheless, the overall clinical use of N2O has declined.”
BackgroundYan, D., Liu, B., Wei, X., Ou, W., Liao, M., Ji, S., Peng, Y., Liu, J., Wu, S., Wang, M., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114867 · Cited by 38
Sakurai, H., Yonezawa, K., Tani, H., Mimura, M., Bauer, M., & Uchida, H. (2022) · Pharmacopsychiatry · doi:10.1055/a-1714-9097 · Cited by 42
“Furthermore, the primary endpoint was not clarified in one study for nitrous oxide [19].”
BackgroundIzumi, Y., Hsu, F., Conway, C. R., Nägele, P., Mennerick, S. J., & Zorumski, C. F. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.06.016 · Cited by 39
Self-citationIntrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
Randomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed PatientsPreprint
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · medRxiv · doi:10.1101/2023.04.28.23289210 · Cited by 26
“Ketamine, a dissociative anesthetic with multiple molecular targets 1,2 , is associated with rapid-acting antidepressant effects in patients with major depressive disorder (MDD) , including those with treatment-resistant depression (TRD) 3–5 .”
InfluentialKim, W. S. H., Dimick, M. K., Omrin, D., Mitchell, R. H. B., Riegert, D., Levitt, A., Schaffer, A., Belo, S., Iazzetta, J., Detzler, G., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13288 · Cited by 24
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Brenna, C. T. A., Goldstein, B. I., Zarate, C. A., & Orser, B. A. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005037 · Cited by 24
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
“…oxide has only been studied using a single dosing session, with a statistically significant benefit detectable two hours post dosing in an open label study [86] and two weeks post dosing for both 25% and 50% N 2 O concentrations versus a 0% N 2 O mixture in a 24-patient cross-over trial [87].”
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 21
Liu, H., Kerzner, J., Demchenko, I., Wijeysundera, D. N., Kennedy, S. H., Ladha, K. S., & Bhat, V. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13432 · Cited by 19
Rech, P., Custodio, R. M., Uggioni, M. L. R., Prestes, G. D. S., Marçal, F., Silveira, V., Dagostin, V. S., Colonetti, T., & da Rosa, M. I. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110869 · Cited by 18
The boon and bane of nitrous oxide
Kronenberg, G., Schoretsanitis, G., Seifritz, E., & Olbrich, S. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01801-3 · Cited by 20
“[38], as the majority of the available studies applied the concentration of 50%.”
InfluentialShao, X., Yan, D., Kong, W., Sun, S., Liao, M., Ou, W., Zhang, Y., Zheng, F., Li, X., Li, L., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115072 · Cited by 18
Synthetic surprise as the foundation of the psychedelic experience
Filippo, R. D., & Schmitz, D. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105538 · Cited by 19
“…Marwaha et al., 2023; Marcantoni et al., 2020), Dextromethor-phan (Tabuteau et al., 2022), nitrous oxide (Varias et al., 2020; Nagele et al., 2015; Nagele et al., 2021), Salvia divinorum (Taylor and Man-zella, 2016), and methoxetamine (Striebel et al., 2017), deliriants like scopolamine (Furey…”
BackgroundPsychedelic Experience: Revealing the Mind
Lyon, A. (2023) · doi:10.1093/oso/9780198843757.001.0001 · Cited by 29
Zheng, Q., Liu, F., Xu, S., Hu, J., Lu, H., & Liu, T. (2023) · Journal of Safety Science and Resilience · doi:10.1016/j.jnlssr.2023.10.002 · Cited by 19
Sertraline modulates hippocampal plasticity via sigma 1 receptors, cellular stress and neurosteroids
Izumi, Y., Reiersen, A. M., Lenze, E. J., Mennerick, S. J., & Zorumski, C. F. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03185-3 · Cited by 14
Self-citationCichon, J., Joseph, T. T., Lu, X., Wasilczuk, A. Z., Kelz, M. B., Mennerick, S. J., Zorumski, C. F., & Nägele, P. (2025) · Nature Communications · doi:10.1038/s41467-025-57951-y · Cited by 17
“These results suggest that at doses found to have antidepressant effects in human patients suffering from TRD 17,18 , N 2 O inhalation drives a rapid activation of the same class of neurons most profoundly affected by chronic stress in rodents (Fig.”
InfluentialSelf-citationLiu, J., Zhao, X., Wei, X., Yan, D., Ou, W., Liao, M., Ji, S., Peng, Y., Wu, S., Wang, M., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115326 · Cited by 13
Linking Hypothermia and Altered Metabolism with TrkB Activation
Alitalo, O., González-Hernández, G., Rosenholm, M., Kohtala, P., Matsui, N., Müller, H. K., Theilmann, W., Klein, A. B., Kärkkäinen, O. K., Rozov, S. V., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00350 · Cited by 11
Anesthetics as Treatments for Depression: Clinical Insights and Underlying Mechanisms
Breault, M. S., Orguc, S., Kwon, O., Kang, G. H., Tseng, B., Schreier, D. R., & Brown, E. N. (2025) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-112723-062031 · Cited by 13
Desmidt, T., Dujardin, P., Andersson, F., Brizard, B., Réméniéras, J.-P., Gissot, V., Arlicot, N., Barantin, L., Espitalier, F., Belzung, C., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02217-6 · Cited by 12
Management of Depression and Anxiety in Perioperative Medicine
Rolfzen, M. L., Nägele, P., Conway, C. R., Gibbons, R. D., & Bartels, K. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005076 · Cited by 13
Self-citationJiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
“This was further confirmed by a follow-up phase II clinical trial [100].”
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 15
“In a later phase II study the same research group was able to confirm the efficacy of nitrous oxide and further found that 25% nitrous oxide also worked comparably well but with fewer side effects [74].”
Escobar, A. J., Krishna, S. R., Flowers, K. M., Abello, A., Gershman, B., Wagner, A. A., Chang, P., Korets, R., Mistretta, C., Schreiber, K. L., et al. (2023) · The Journal of Urology · doi:10.1097/ju.0000000000003789 · Cited by 11
“6 Historical studies on the risks of occupational exposure by staff to N 2 O led to reduced utilization of N 2 O in medical procedures in the US.”
BackgroundLiu, Y., Hu, Q., Xu, S., Li, W., Liu, J., Han, L., Mao, H., Cai, F., Liu, Q., Zhu, R., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.11.077 · Cited by 13
Alitalo, O., Kohtala, S., Rosenholm, M., Saarreharju, R., González-Hernández, G., Sarparanta, M. P., Rozov, S. V., & Rantamäki, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110172 · Cited by 11
What is better for psychiatry: Titrated or fixed concentrations of nitrous oxide?
Gillman, M. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.773190 · Cited by 8
“Simply, the concentrations of N2O are always lower than a 50% (1, 4–6, 15) or 25% (15) fixed mixture administered through a strapped facial mask, because dental flowmeters use a semi-open nasal mask system (7, 8, 13, 14) Further, dental flowmeters ensure that the maximum concentration, as per the rotameters is 70% (7,…”
BackgroundMethodInfluentialDai, R., Huang, Z., Larkin, T. E., Tarnal, V., Picton, P., Vlisides, P. E., Janke, E., McKinney, A., Hudetz, A. G., Harris, R. E., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05678-1 · Cited by 11
Persistent Brain Connectivity Changes in Healthy Volunteers Following Nitrous Oxide Inhalation
Palanca, B. J. A., Conway, C. R., Zeffiro, T. A., Gott, B. M., Nguyen, T. A., Janski, A. M., Jain, N., Komen, H., Burke, B. A., Zorumski, C. F., et al. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2023.01.006 · Cited by 10
“Two studies have now demonstrated that antidepressant effects of a single nitrous oxide inhalation can persist for at least 1 to 2 weeks (3,4).”
BackgroundSelf-citationde León-Martínez, V., Kumar, R., Nägele, P., Palanca, B. J., Gott, B. M., Janski, A. M., Zorumski, C. F., & Conway, C. R. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22br14725 · Cited by 11
Self-citationQiu, Y., Li, L., Duan, A., Wang, M., Xie, M., Chen, Z., & Wang, Z. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06449-w · Cited by 8
“For safety, we analyzed the most common AEs in studies.”
BackgroundInfluentialUltrabrief pulse electroconvulsive therapy for depression: a systematic review and meta-analysis
Jelovac, A., & McLoughlin, D. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03327-z · Cited by 9
Ladha, K. S., Lee, J., Mattina, G. F., Pazmino‐Canizares, J., Wijeysundera, D. N., Nezhad, F. G., Philip, K., Tassone, V. K., Adamsahib, F., Bhat, V., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297330 · Cited by 7
Rozov, S. V., Saarreharju, R., Khirug, S., Storvik, M., Rivera, C., & Rantamäki, T. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176426 · Cited by 6
Propofol for treatment resistant depression: A randomized controlled trialPreprint
Tadler, S. C., Jones, K. G., Lybbert, C., Huang, J. C., Jawish, R., Solzbacher, D., Kendrick, E., Pierson, M. D., Weischedel, K., Rana, N., et al. (2023) · medRxiv · doi:10.1101/2023.09.12.23294678 · Cited by 8
Nitrous oxide for the treatment of depression: a systematic review and meta-analysis
Gill, K., de Cates, A. N., Wiseman, C. E., Murphy, S. E., Williams, E., Harmer, C. J., Morales‐Muñoz, I., & Marwaha, S. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.106023 · Cited by 7
“49,50,52,54 Funnel plot analysis (Figure S2, Supplement 4) of four studies showed moderate asymmetry in the distribution of effect sizes at 24 h post-inhalation of 50% N2O, 49,50,52,54 with one study reporting null or negative effects.”
InfluentialA synopsis of multitarget therapeutic effects of anesthetics on depression
Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 7
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Rapid antidepressant potential of nitrous oxide: current state and major questions
Zorumski, C. F., Cichon, J., Izumi, Y., Zeffiro, T. A., Mennerick, S. J., Nägele, P., & Conway, C. R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03439-6 · Cited by 7
Self-citationBetter Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Siegel, J. S., Pearson, C. S., & Lenze, E. J. (2023) · PubMed Central · Cited by 7
Myles, P. S., Kulkarni, J., Kasza, J., Wallace, S. K. A., Deng, C., Turbić, A., Aykanat, V. M., Conway, C. R., Brown, F., Lee, R., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100504 · Cited by 8
“Although we and others have conducted some preliminary studies of nitrous oxide in similar populations, each supporting proof of concept, this evidence was restricted to short-term (1 – 2 weeks) follow-up (13,14,18).”
Self-citationNägele, P., Conway, C. R., & Zorumski, C. F. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0900 · Cited by 6
Self-citationTreatments for major depression
Myles, P. S., Kulkarni, J., & Nägele, P. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00950-9 · Cited by 5
Regulating the oxides of nitrogen – popping the myths
Ferreira, P., & Nutt, D. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221085221 · Cited by 4
“One is in the treatment of depression that has failed to respond to conventional treatments (Nagele et al., 2021).”
BackgroundEscobar, A. J., Vasdev, R. M. S., Gallo, M., Softness, K. A., Wang, H. S., & Rayala, H. J. (2024) · European Urology Open Science · doi:10.1016/j.euros.2024.08.002 · Cited by 3
“Interestingly, a recent study showed a fourfold increase in side effects with N 2 O at 50% in comparison to 25% [23].”
BackgroundExamining memory reconsolidation as a mechanism of nitrous oxide’s antidepressant action
Williams, E., Taujanskaitė, U., Kamboj, S. K., Murphy, S. E., & Harmer, C. J. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-02049-0 · Cited by 45
“Most pertinent to the current review, however, is the demonstration that N 2 O exhibits rapid-acting, yet somewhat transient, antidepressant effects in individuals with TRD [18, 23].”
Conway, C. R., Palanca, B. J. A., Zeffiro, T. A., Gott, B. M., Brown, F., de León-Martínez, V., Barnes, L., Nguyen, T. A., Xiong, W., Lessov‐Schlaggar, C. N., et al. (2024) · medRxiv · doi:10.1101/2024.08.12.24311729 · Cited by 6
Self-citationKronenberg, G., Müller, A. M., Seifritz, E., & Olbrich, S. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01502-9 · Cited by 2
“1a), corroborating previous findings [1, 2].”
BackgroundLadha, K. S., Lee, J., Mattina, G. F., Pazmino‐Canizares, J., Wijeysundera, D. N., Nezhad, F. G., Tassone, V. K., Adamsahib, F., Lou, W. Y. W., Kennedy, S. H., et al. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10823 · Cited by 3
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0009 · Cited by 1
Application of Anesthetic Agents in Depression
Vutskits, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93273-8.00026-2 · Cited by 1
Deux cents ans d’histoire des usages et mésusages du protoxyde d’azote
Raffour, E. C., Durin, L., Monard, A., & Giagnorio, R. (2024) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2024.03.006 · Cited by 1
Beyond surgery: Repurposing anesthetics for treatment of central nervous system disorders
Mielko, J., Pakulska, J., Oszczyk, A., Lustyk, K., Pytka, K., & Sałaciak, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111386 · Cited by 1
Inhaled gases for treatment-resistant major depression
Conway, C. R., Mickey, B. J., Palanca, B. J. A., Tadler, S. C., & Nägele, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00033-5 · Cited by 2
Self-citationInsights Into the Effects of Ketamine on the Opioid System
Zorumski, C. F., & Mennerick, S. J. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.07.005 · Cited by 1
Self-citationUnderstanding ketamine subjective effects
Dahan, A., & Niesters, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00008-4 · Cited by 1
Li, C., Wang, Z., Ye, X., Lv, J., Chen, F., Zhang, Y., Liu, J., Li, X., Duan, J., Wang, Y., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1692751 · Cited by 3
Cichon, J. (2026) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000008168 · Cited by 1
Gillman, M. A. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230330122010 · Cited by 1
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0001 · Cited by 1
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0005 · Cited by 1
Nitrous Oxide in the Treatment of Depression: A Brief Review
Hughes, M. E. (2024) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2024.200207 · Cited by 1
Rebound electroencephalographic responses to nitrous oxide exposure in men
Valtonen, P., Rozov, S. V., Annala, I., Järventausta, K., Subramaniyam, N. P., Tenhunen, M. L., Hyttinen, J., Yli‐Hankala, A., Rantamäki, T., & Kalliomäki, M. (2025) · Journal of Neurophysiology · doi:10.1152/jn.00275.2024 · Cited by 3
Treatments for major depression – Authors' reply
Marwaha, S., Young, A. H., Suppes, T. M., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00952-2 · Cited by 1
Valtonen, P., Rozov, S. V., Annala, I., Järventausta, K., Subramaniyam, N. P., Tenhunen, M. L., Hyttinen, J., Yli‐Hankala, A., Rantamäki, T., & Kalliomäki, M. (2023) · doi:10.22541/au.169636012.26587057/v1 · Cited by 1
Cichon, J., Joseph, T. T., Wasilczuk, A. Z., Markman, D., Kelz, M. B., & Nägele, P. (2024) · Research Square · doi:10.21203/rs.3.rs-3706278/v1 · Cited by 1
Kohtala, S., Parekh, P. K., Baramaki, I., Kohtala, P., Ilkka, L., Antila, H., Lee, F. S., & Liston, C. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.13.638096 · Cited by 2
Physiological basis underlying antidepressant-induced activation of TrkB receptorsPreprint
Alitalo, O., Kohtala, S., Rosenholm, M., Kohtala, P., Saarreharju, R., Matsui, N., González-Hernández, G., Müller, H. K., Theilmann, W., Sarparanta, M. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.30.458151
“We used 60 min exposure of 50% N2O (in O2), as its rapid and sustained antidepressant effects have been recently revealed (Nagele et al., 2021), but the underlying mechanism remains obscure.”
BackgroundMethodPerspective Chapter: NMDA Treatments for CNS Disorders
Lin, C.-H., Shih, P., & Tsai, G. E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100528
Du gaz hilarant contre la dépression
Jacquemont, G. (2021) · Cerveau & Psycho · doi:10.3917/cerpsy.135.0007
Effects of nitrous oxide and ketamine on the prefrontal cortex in mice: a comparative studyPreprint
Rozov, S. V., Saarreharju, R., Khirug, S., Storvik, M., Rivera, C., & Rantamäki, T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.19.508563
“Recently, N2O has shown promise as a rapid-acting antidepressant [1,2], likely owing to its antagonistic effects on N-methyl-D-aspartate receptors (NMDARs), similar to those of ketamine.”
BackgroundCanonical and Non-Canonical Psychedelic Drugs Induce Common Network Changes in Human CortexPreprint
Dai, R., Larkin, T. E., Huang, Z., Tarnal, V., Picton, P., Vlisides, P. E., Janke, E., McKinney, A., Hudetz, A. G., Harris, R. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.14.512285
“16 nitrous oxide is as effective as a 50% concentration for treatment-resistant major depression (19).”
Background(2023) · The Lancet · doi:10.1016/s0140-6736(23)01232-1
(2023) · The Lancet · doi:10.1016/s0140-6736(23)01256-4
Rao, P., & Morandini, H. A. E. (2023) · Journal of Indian Association for Child and Adolescent Mental Health · doi:10.1177/09731342231179036 · Cited by 1
The Taylor Family Institute at Washington University: Novel Treatments in Psychiatry.
Zorumski, C. F., & Mennerick, S. J. (2023) · PubMed Central
Self-citation(2021) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2021.3.3
“Results from another phase II study examining 1hour inhalation of 50% nitrous oxide have not been reported yet, and an ongoing phase II RCT is investi gating the effects of nitrous oxide at different concen trations [44].”
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0010
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0011
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0008
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0006
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0012
(2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.002.0006
Metadata
- Authors
- Nagele, P., Palanca, B. J., Gott, B., Brown, F., Barnes, L., Nguyen, T., Xiong, W., Salloum, N. C., Espejo, G. D., Lessov-Schlaggar, C. N., Jain, N., Cheng, W. W. L., Komen, H., Yee, B., Bolzenius, J. D., Janski, A., Gibbons, R., Zorumski, C. F., & Conway, C. R.
- Affiliations
- Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL 60637, USA.
- Washington University in St. Louis (US)
- University of Chicago (US)
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2021-06-09
- Volume
- 13
- Issue
- 597
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3170628472
- Cited by
- 133
- References
- 29
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 26 · 2023: 52 · 2022: 15 · 2021: 5
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (24593)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- major depressive disorder, treatment-resistant depression, adverse effects, depression treatment
- MeSH terms
- Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Humans, Nitrous Oxide, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.